October 30, 2013 | Israeli company CartiHeal, which develops innovative, cell-free cartilage regeneration technology, has announced that it received an additional $5 million funding in cash from its existing investors: Elron, Accelmed and Access Medical Ventures. The proceeds will be used to expand ongoing post-marketing clinical studies of Cartiheal’s signature product Agili-C in Europe.
Subscribe to NoCamels weekly newsletter and get our top stories
Facebook comments